Effect of GBR 12909 and fluoxetine on the acute and long term changes induced by MDMA ('ecstasy') on the 5-HT and dopamine concentrations in mouse brain

Neuropharmacology

Volumn 40, Issue 1, 2001, Pages 65-74

  O'Shea, E ^a   Esteban, B ^a   Camarero, J ^a   Green, A R ^b   Colado, M I ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b DE MONTFORT UNIVERSITY   (United Kingdom)

Author keywords

3,4 Methylenedioxymethamphetamine; 5 Hydroxytryptamine; Dopamine; Ecstasy; Fluoxetine; GBR 12909; Hyp erthermia; MDMA; Neuroprotection

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 5 HYDROXYINDOLEACETIC ACID; DOPAMINE; DOPAMINE UPTAKE INHIBITOR; FLUOXETINE; HOMOVANILLIC ACID; SEROTONIN; VANOXERINE; BIOGENIC AMINE; PIPERAZINE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; SEROTONIN UPTAKE INHIBITOR;

ANIMAL TISSUE; ARTICLE; BODY TEMPERATURE; BRAIN PROTECTION; CATECHOLAMINE BRAIN LEVEL; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; MALE; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECTUM TEMPERATURE; SEROTONIN RELEASE; ANIMAL; BRAIN LEVEL; DRUG ANTAGONISM; METABOLISM;

3,4-DIHYDROXYPHENYLACETIC ACID; ANIMALS; BIOGENIC MONOAMINES; BODY TEMPERATURE; BRAIN CHEMISTRY; DOPAMINE; DOPAMINE UPTAKE INHIBITORS; FLUOXETINE; HOMOVANILLIC ACID; MALE; MICE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PIPERAZINES; SEROTONIN; SEROTONIN AGENTS; SEROTONIN UPTAKE INHIBITORS;

EID: 0035227059     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3908(00)00106-4     Document Type: Article

References (55)

1. The dopamine uptake inhibitor GBR 12909: Selectivity and molecular mechanism of action
2. Striatal dopamine release in vivo following neurotoxic doses of methamphetamine and effect of the neuroprotective drugs, chlormethiazole and dizocilpine
3. 3H]paroxetine-labeled serotonin uptake sites
4. MDMA-induced neurotoxicity: Parameters of degeneration and recovery of brain serotonin neurons
5. Effects of a cold environment or age on methamphetamine-induced dopamine release in the caudate putamen of female rats
6. Further studies of the role of hyperthermia in methamphetamine neurotoxicity
7. Superoxide radicals mediate the biochemical effects of methylenedioxymethamphetamine (MDMA): Evidence from using CuZn-superoxide dismutase transgenic mice
8. A study of the mechanism of MDMA ('ecstasy') - Induced neurotoxicity of 5-HT neurones using chlormethiazole, dizocilpine and other protective compounds
9. Role of hyperthermia in the protective action of clomethiazole against MDMA ('ecstasy') - Induced neurodegeneration, comparison with the novel NMDA channel blocker AR-R15896
10. In vivo evidence for free radical involvement in the degeneration of rat brain 5-HT following administration of MDMA ('ecstasy') and p-chloroamphetamine but not the degeneration following fenfluramine
11. Studies on the role of dopamine in the degeneration of 5-HT nerve endings in the brain of Dark Agouti rats following 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy') administration
12. 2+-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine
13. Similar brain concentrations of MDMA have different neurotoxic effects following central or peripheral drug administration
14. Acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on monoamines in rat caudate
15. The neurotoxic effects of methamphetamine on 5-hydroxytryptamine and dopamine in brain: Evidence for the protective effect of chlormethiazole
16. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or 'ecstasy')
17. 2 receptor agonists
18. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: Implications for serotonin-dopamine interactions
19. Behavioral properties of GBR 12909, GBR 13069 and GBR 13098: Specific inhibitors of dopamine uptake
20. Chlormethiazole, dizocilpine and haloperidol prevent the degeneration of serotonergic nerve terminals induced by administration of MDMA ('Ecstasy') to rats
21. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its congeners
22. The neuronal nitric oxide synthase inhibitor, 7-nitroindazole, protects against methamphetamine-induced neurotoxicity in vivo
23. Overexpression of human copper/zinc superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxymethamphetamine (ecstasy)
24. MDMA induced dopamine release in vivo: Role of endogenous serotonin
25. Protection by MK 801 and other drugs of methylenedioxymethamphetamine (MDMA) neurotoxicity in rats and mice
26. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part II: Radioligand binding and autoradiography studies
27. Differences between rats and mice in MDMA (methylenedioxymethylamphetamine) neurotoxicity
28. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat
29. Differential toxic effects of methamphetamine (METH) and methylenedioxymethamphetamine (MDMA) in multidrug-resistant (mdr1a) knockout mice
30. The effects of monoamine uptake inhibitors and methamphetamine on neostriatal 6-hydroxydopamine (6-OHDA) formation, short-term monoamine depletions and locomotor activity in the rat
31. Dopamine uptake inhibitors block long term neurotoxic effects of methamphetamine
32. Environment-, drug- and stress-induced alterations in body temperature affect the neurotoxicity of substituted amphetamines in the C57BL/6J mouse
33. Neurotoxicity of MDMA and related compounds: Anatomic studies
34. Ketanserin pretreatment attenuates MDMA-induced dopamine release in the striatum as measured by in vivo microdialysis
35. Microdialysis studies on 3,4-methylenedioxymethamphetamine-induced dopamine release: Effect of dopamine uptake inhibitors
36. Neurotoxicity profiles of substituted amphetamines in the C57BL/6J mouse
37. Methylenedioxyamphetamine (MDA) and methylenedioxymethamphetamine cause ablation of serotonergic axon terminals in forebrain: Immunocytochemical evidence
38. Lack of serotonin neurotoxicity after intraraphe microinjection of (+)-3,4-methylenedioxymethamphetamine (MDMA)
39. Methylenedioxymethamphetamine-induced serotonin deficits are followed by partial recovery over a 52-week period. Part I: Synaptosomal uptake and tissue concentrations
40. Reserpine attenuates D-amphetamine and MDMA-induced transmitter release in vivo: A consideration of dose, core temperature and dopamine synthesis
41. Neurotoxicity of the psychedelic amphetamine, methylenedioxymethamphetamine
42. In vitro and in vivo neurochemical effects of methylenedioxymethamphetamine on striatal monoaminergic systems in the rat brain
43. Depression of rat brain tryptophan hydroxylase activity following the acute administration of methylenedioxymethamphetamine
44. Direct central effects of acute methylenedioxymethamphetamine on serotonergic neurons
45. 2 receptor antagonists protect against the neurotoxicity of methylenedioxymethamphetamine in rats
46. Neurotoxicity of MDMA: Neurochemical effects
47. Alterations in hippocampal function following repeated exposure to the amphetamine derivative methylenedioxymethamphetamine ('Ecstasy')
48. 3H]monoamines into synaptosomes for different regions of rat brain
49. 3,4-Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): Pharmacology and toxicology in animals and humans
50. The effects of 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxyamphetamine (MDA) on monoaminergic systems in the rat brain
51. Differences in the central serotonergic effects of methylenedioxymethamphetamine (MDMA) in mice and rats
52. Role of endogenous dopamine in the central serotonergic deficits induced by 3,4-methylenedioxymethamphetamine
53. Aryl 1,4-dialk(en)ylpiperazines as selective and very potent inhibitors of dopamine uptake
54. The effects of methylenedioxymethamphetamine (MDMA, 'Ecstasy') on monoaminergic neurotransmission in the central nervous system
55. 3H]methylenedioxyamphetamine: Characterization suggest the presence of a factor responsible for maintaining sequestration